{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:58:34Z","timestamp":1787021914939,"version":"build-2736575974"},"reference-count":67,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T00:00:00Z","timestamp":1393372800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0088203","type":"journal-article","created":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T16:49:32Z","timestamp":1393433372000},"page":"e88203","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Temsirolimus Inhibits Proliferation and Migration in Retinal Pigment Epithelial and Endothelial Cells via mTOR Inhibition and Decreases VEGF and PDGF Expression"],"prefix":"10.1371","volume":"9","author":[{"given":"Raffael","family":"Liegl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Siedlecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Haritoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anselm","family":"Kampik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Kernt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,2,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","article-title":"Mechanisms of age-related macular degeneration","volume":"75","author":"J Ambati","year":"2012","journal-title":"Neuron"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"LS Lim","year":"2012","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s11892-012-0283-6","article-title":"Current epidemiology of diabetic retinopathy and diabetic macular edema","volume":"12","author":"J Ding","year":"2012","journal-title":"Curr Diab Rep"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4103\/0301-4738.100542","article-title":"The worldwide epidemic of diabetic retinopathy","volume":"60","author":"Y Zheng","year":"2012","journal-title":"Indian J Ophthalmol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ophtha.2012.07.038","article-title":"Vascular endothelial growth factor a in intraocular vascular disease","volume":"120","author":"JW Miller","year":"2013","journal-title":"Ophthalmology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/CS20120588","article-title":"Advances in our understanding of diabetic retinopathy","volume":"125","author":"AW Stitt","year":"2013","journal-title":"Clin Sci (Lond)"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00109-013-0993-5","article-title":"Ocular neovascularization","volume":"91","author":"PA Campochiaro","year":"2013","journal-title":"J Mol Med (Berl)"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.preteyeres.2011.05.002","article-title":"Inflammation in diabetic retinopathy","volume":"30","author":"J Tang","year":"2011","journal-title":"Prog Retin Eye Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1096\/fj.03-1476fje","article-title":"A central role for inflammation in the pathogenesis of diabetic retinopathy","volume":"18","author":"AM Joussen","year":"2004","journal-title":"FASEB J"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Cheung LK, Eaton A (2013) Age-Related Macular Degeneration. Pharmacotherapy.","DOI":"10.1002\/phar.1264"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1042\/CS20120212","article-title":"Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy","volume":"124","author":"JL Wilkinson-Berka","year":"2013","journal-title":"Clin Sci (Lond)"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Muether PS, Neuhann I, Buhl C, Hermann MM, Kirchhof B, <etal>et al<\/etal>.. (2013) INTRAOCULAR GROWTH FACTORS AND CYTOKINES IN PATIENTS WITH DRY AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina.","DOI":"10.1097\/IAE.0b013e318285cd9e"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/bjo.2010.182162","article-title":"Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF","volume":"94","author":"M Kernt","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e68149","DOI":"10.1371\/journal.pone.0068149","article-title":"Differences in aqueous concentrations of cytokines in macular edema secondary to branch and central retinal vein occlusion","volume":"8","author":"J Feng","year":"2013","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/bjophthalmol-2012-301913","article-title":"Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion","volume":"96","author":"WJ Lee","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ajo.2012.04.020","article-title":"Aflibercept for age-related macular degeneration: a game-changer or quiet addition?","volume":"154","author":"DJ Browning","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2012.07.058","article-title":"Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology","volume":"119","author":"AC Ho","year":"2012","journal-title":"Ophthalmology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2337\/dc10-0493","article-title":"Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study","volume":"33","author":"P Massin","year":"2010","journal-title":"Diabetes Care"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"PJ Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"JS Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"N Ferrara","year":"2004","journal-title":"Endocr Rev"},{"key":"ref22","first-page":"426769","article-title":"Hypoxia-induced oxidative stress in ischemic retinopathy","volume":"2012","author":"SY Li","year":"2012","journal-title":"Oxid Med Cell Longev"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1172\/JCI13374","article-title":"Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to the dance","volume":"108","author":"GL Semenza","year":"2001","journal-title":"J Clin Invest"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/joim.12019","article-title":"VEGFA and tumour angiogenesis","volume":"273","author":"L Claesson-Welsh","year":"2013","journal-title":"J Intern Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"9739","DOI":"10.1073\/pnas.0804123105","article-title":"Class 1A PI3K regulates vessel integrity during development and tumorigenesis","volume":"105","author":"TL Yuan","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nature06892","article-title":"Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration","volume":"453","author":"M Graupera","year":"2008","journal-title":"Nature"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1517\/13543776.2011.584871","article-title":"Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review","volume":"21","author":"A Zask","year":"2011","journal-title":"Expert Opin Ther Pat"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2146\/ajhp100020","article-title":"Mammalian target of rapamycin: biological function and target for novel anticancer agents","volume":"67","author":"EB Borders","year":"2010","journal-title":"Am J Health Syst Pharm"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000343063","article-title":"Mammalian Target of Rapamycin as a Rational Therapeutic Target for Breast Cancer Treatment","volume":"84","author":"PM Lorusso","year":"2012","journal-title":"Oncology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1517\/14740338.2012.713344","article-title":"Temsirolimus: a safety and efficacy review","volume":"11","author":"RM Bukowski","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"897025","DOI":"10.1155\/2013\/897025","article-title":"Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis","volume":"2013","author":"P Frost","year":"2013","journal-title":"J Oncol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/jjco\/hys110","article-title":"Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma","volume":"42","author":"Y Sun","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1200\/JCO.2010.33.4649","article-title":"Phase I study of temsirolimus in pediatric patients with recurrent\/refractory solid tumors","volume":"29","author":"SL Spunt","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jcrs.2008.10.052","article-title":"Cytoprotective effects of a blue light-filtering intraocular lens on human retinal pigment epithelium by reducing phototoxic effects on vascular endothelial growth factor-alpha, Bax, and Bcl-2 expression","volume":"35","author":"M Kernt","year":"2009","journal-title":"J Cataract Refract Surg"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"T Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1084\/jem.115.3.453","article-title":"The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes","volume":"115","author":"S Boyden","year":"1962","journal-title":"J Exp Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/bjo.2010.182162","article-title":"Kernt M, Neubauer AS, Liegl RG, Hirneiss C, Alge CS, et al. Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF","volume":"94","journal-title":"Br J Ophthalmol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"e54918","DOI":"10.1371\/journal.pone.0054918","article-title":"A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models","volume":"8","author":"H Zhang","year":"2013","journal-title":"PLoS One"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1158\/1078-0432.CCR-07-0781","article-title":"Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma","volume":"13","author":"JG Kuhn","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref40","first-page":"7291","article-title":"Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy","volume":"62","author":"JS Eshleman","year":"2002","journal-title":"Cancer Res"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Cohen SY, Dubois L, Ayrault S, Dourmad P, Delahaye-Mazza C, <etal>et al<\/etal>.. (2013) Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010. Graefes Arch Clin Exp Ophthalmol.","DOI":"10.1007\/s00417-013-2338-z"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/157339912800840488","article-title":"Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues","volume":"8","author":"MW Stewart","year":"2012","journal-title":"Curr Diabetes Rev"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"e42701","DOI":"10.1371\/journal.pone.0042701","article-title":"A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard","volume":"7","author":"C Schmucker","year":"2012","journal-title":"PLoS One"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1097\/IAE.0b013e318240a516","article-title":"Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings","volume":"32","author":"SY Cohen","year":"2012","journal-title":"Retina"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/nyas.12060","article-title":"Challenges in the clinical development of PI3K inhibitors","volume":"1280","author":"C Massacesi","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1172\/JCI44303","article-title":"mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice","volume":"121","author":"C Zhao","year":"2011","journal-title":"J Clin Invest"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.3816\/CBC.2010.s.016","article-title":"Targeting endocrine resistance: is there a role for mTOR inhibition?","volume":"10","author":"A Sheri","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2009.10.011","article-title":"Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth","volume":"36","author":"JJ Gibbons","year":"2009","journal-title":"Semin Oncol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/138920310791824093","article-title":"The complexes of mammalian target of rapamycin","volume":"11","author":"H Zhou","year":"2010","journal-title":"Curr Protein Pept Sci"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1476-5381.2012.02227.x","article-title":"Silibinin inhibits VEGF secretion and age-related macular degeneration in a hypoxia-dependent manner through the PI-3 kinase\/Akt\/mTOR pathway","volume":"168","author":"CH Lin","year":"2013","journal-title":"Br J Pharmacol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"e18921","DOI":"10.1371\/journal.pone.0018921","article-title":"Mature peripheral RPE cells have an intrinsic capacity to proliferate; a potential regulatory mechanism for age-related cell loss","volume":"6","author":"I Kokkinopoulos","year":"2011","journal-title":"PLoS One"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1167\/iovs.04-0753","article-title":"Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo","volume":"46","author":"YS Kwon","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3109\/02713683.2012.663855","article-title":"Interaction between VEGF and calcium-independent phospholipase A2 in proliferation and migration of retinal pigment epithelium","volume":"37","author":"AK Kehler","year":"2012","journal-title":"Curr Eye Res"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"e60709","DOI":"10.1371\/journal.pone.0060709","article-title":"mTOR Inhibition Elicits a Dramatic Response in PI3K-Dependent Colon Cancers","volume":"8","author":"DA Deming","year":"2013","journal-title":"PLoS One"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Martin LA, Andre F, Campone M, Bachelot T, Jerusalem G (2013) mTOR inhibitors in advanced breast cancer: Ready for prime time? Cancer Treat Rev.","DOI":"10.1016\/j.ctrv.2013.02.005"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1089\/ars.2011.3906","article-title":"Alterations to the blood-retinal barrier in diabetes: cytokines and reactive oxygen species","volume":"15","author":"T Frey","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/08977194.2011.639300","article-title":"Axitinib modulates hypoxia-induced blood-retina barrier permeability and expression of growth factors","volume":"30","author":"M Kernt","year":"2012","journal-title":"Growth Factors"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/BF03401566","article-title":"Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen","volume":"1","author":"DT Shima","year":"1995","journal-title":"Mol Med"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1001\/archopht.1995.01100120068012","article-title":"Hypoxic regulation of vascular endothelial growth factor in retinal cells","volume":"113","author":"LP Aiello","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"13957","DOI":"10.1074\/jbc.M511763200","article-title":"Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase\/Rho\/ROCK and c-Myc","volume":"281","author":"Y Mizukami","year":"2006","journal-title":"J Biol Chem"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"DJ Hicklin","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref62","first-page":"5879","article-title":"Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3&apos;-kinase and distinct from that induced by hypoxia","volume":"60","author":"A Maity","year":"2000","journal-title":"Cancer Res"},{"key":"ref63","first-page":"3259","article-title":"Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer","volume":"8","author":"N Reinmuth","year":"2002","journal-title":"Clin Cancer Res"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1593\/neo.05820","article-title":"CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR\/Hif-1alpha\/VEGF signaling","volume":"8","author":"X Wan","year":"2006","journal-title":"Neoplasia"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1869-5760-3-32","article-title":"Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study","volume":"3","author":"QD Nguyen","year":"2013","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1470-2045(11)70124-3","article-title":"Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial","volume":"12","author":"S Negrier","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Danesi R, Boni JP, Ravaud A (2013) Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implications. Cancer Treat Rev.","DOI":"10.1016\/j.ctrv.2012.12.012"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0088203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T20:41:19Z","timestamp":1565210479000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0088203"}},"subtitle":[],"editor":[{"given":"Olaf","family":"Strau\u00df","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,26]]},"references-count":67,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0088203","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,26]]}}}